| May 31 |
Valneva nabs EU backing for Chikungunya vaccine
|
| May 31 |
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
|
| May 21 |
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
|
| May 13 |
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
|
| May 8 |
Cracking The Code: Understanding Analyst Reviews For Valneva
|
| May 7 |
Valneva reports Q1 results
|
| May 7 |
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
|
| May 6 |
Declaration of shares and voting rights April 30, 2024 - VALNEVA SE
|
